Lempo Therapeutics is a preclinical biotech company that uses gene editing to modify the immune system for attenuating severe chronic diseases. The companys novel, patented treatment uses an ex vivo stem cell gene-editing technique to minimize the collateral damage caused by immune system activity, thereby significantly mitigating disease progression. Lempos initial focus is on treating pulmonary arterial hypertension (PAH), a rare and devastating cardiovascular disease that leads to heart failure and death if left untreated. The companys concept has already been proven effective in animal models for the treatment of Alzheimers disease, multiple sclerosis, cardiovascular diseases, and more.